What is Raymond James’ Estimate for TSE:MDP FY2025 Earnings?

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Raymond James boosted their FY2025 EPS estimates for shares of Medexus Pharmaceuticals in a report issued on Monday, February 3rd. Raymond James analyst M. Freeman now expects that the company will earn $0.07 per share for the year, up from their prior estimate of $0.03. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.51) EPS, FY2028 earnings at $2.10 EPS and FY2029 earnings at $3.05 EPS.

Other equities research analysts also recently issued research reports about the company. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Ventum Financial lifted their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Stifel Nicolaus lowered shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the stock from C$6.00 to C$3.45 in a research note on Friday. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, one has assigned a buy rating and five have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Strong Buy” and a consensus price target of C$5.49.

Medexus Pharmaceuticals Stock Performance

Shares of MDP opened at C$3.21 on Thursday. The stock has a 50-day moving average of C$3.53 and a two-hundred day moving average of C$2.82. The stock has a market cap of C$78.74 million, a P/E ratio of 64.20 and a beta of 1.96. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.